N/A
N=40
Glycocalyx Damage in Critically Ill Patients
Critical Illness
Bottom Line
View on ClinicalTrials.gov: NCT03146585 ↗Enrolled (actual)
40
Serious AEs
—
Results posted
Mar 2020
Primary outcome: Primary: Perfused Boundary Region (PBR) in One Week — 1.95; 1.97; 2.02 micrometer
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- PBR assessment (Device)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- University Hospital Hradec Kralove
- Primary completion
- Dec 2017
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Perfused Boundary Region (PBR) in One Week |
1.95; 1.97; 2.02 | — |
Summary
The hypothesis to be tested: GCX damage and its dynamics correlate to various patient related factors and to using organ-supporting measures. There is a correlation between length of organ support and GCX damage.
The aim of the study: Evaluation of the relationship between GCX damage and duration of various organ supporting measures.
Type of the study: Observational. Subjects: Adult patients admitted to ICU and requiring organ supporting therapy.
Sample size: We plan enrollment of 75 patients on invasive ventilatory support in the duration of least 5 days, 50 patients on renal supporting therapy lasting at least 5 days and 20 patients with target temperature management for neuroprotection.
Intervention: none Data to be recorded and analysed: Demographics, type of patients (trauma, post surgical, medical, after cardiac arrest), severity score - Apache II, SOFA, fluid balance, presence of delirium, clinical outcome, sublingual microcirculation by SDF imaging at time points: before or at the start of organ support, after 24 hours (day 1), day 3, 5, 7 and/or at discharge or before death, microcirculatory data, and Perfused Boundary Region.
Eligibility Criteria
Inclusion Criteria
- adult patients admitted to ICU
- artifitial ventilation
- renal replacement therapy
- targeted temperatura management
Exclusion Criteria
- pregnant women
Data sourced from ClinicalTrials.gov (NCT03146585). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.